生物标志物 生物标志物
Julie Parker-Garza1, Tiffany F Kautz2, Sudha Seshadri3
1Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
临床实验室改进修正 (CLIA) 批准获得了Fujirebio Lumipulse粉样蛋白-β (AB) 42:40测定. 这确保了准确的阿尔茨海默病 (AD) 生物标志物结果用于临床诊断和个性化医疗.
科学领域:
- 临床诊断 临床诊断 临床诊断
- 生物标志物试验验证验证
- 阿尔茨海默病的研究研究.
背景情况:
- 临床实验室改进修正 (CLIA) 对于规范实验室测试的准确性和可靠性至关重要.
- 阿尔茨海默病 (AD) 生物标志物对于早期检测,诊断和治疗至关重要,需要CLIA批准才能进行临床整合.
- 富吉雷比奥Lumipulse粉样蛋白-β (AB) 42:40脑脊液 (CSF) 试验最近获得了FDA的批准,需要获得临床使用的CLIA认证.
研究的目的:
- 详细说明获得临床实验室改进修正案 (CLIA) 对阿尔茨海默病 (AD) 生物标志物批准的过程和要求.
- 解释Fujirebio Lumipulse AB 42:40 CSF测定所需的具体步骤和验证,以满足CLIA认证标准.
- 证明成功获得了新型AD生物标志物试验的CLIA认证.
主要方法:
- 对阿尔茨海默病 (AD) 生物标志物的临床实验室改进修订 (CLIA) 过程进行了审查.
- 使用Lumipulse G1200分析仪在CSF中执行了AB 42:40比率的验证协议.
- 确保遵守CLIA的工作人员,监测和文件,以获得符合性证书,使用生物银行CSF在两个实验室设置中进行盲目技术人员评估.
主要成果:
- 通过满足准确性,可重复性和临床效用要求,获得了Fujirebio AD生物标志物测试的临床实验室改进修改 (CLIA) 认证.
- 在两个不同的实验室站点之间的验证测试中证明了高相关性 (R2=0.9819),证实了测试可靠性.
- 成功满足了CLIA认证的所有标准,为AB 42:40 CSF试验的临床整合铺平了道路.
结论:
- 通过CLIA认证,Fujirebio Lumipulse AB 42:40生物标志物结果可用于阿尔茨海默病 (AD) 的临床诊断和研究.
- CLIA的批准证实了跨临床环境和患者群体的生物标志物测定的一致性,验证了Fujirebio CSF AB42:40测试.
- 临床实验室改进修正 (CLIA) 批准对于使AD生物标志物可用于常规临床应用,精准医学和早期干预策略至关重要.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516